References
- Sogabe Y, Oshima K, Azumi A, et al. Location and frequency of lesions in patients with IgG4-related ophthalmic diseases. Graefes Arch Clin Exp Ophthalmol. 2014;252:531–538. doi:10.1007/s00417-013-2548-4.
- Kashani I, Rajak SN, Kearney DJ, et al. IgG4 staining in thyroid eye disease. OPRS. 2017;33(3S):S183–S185.
- McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part I: Background and pathology. Oprs. 2015;31(2):83–88.
- Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–1192. doi:10.1038/modpathol.2012.72.
- Ginat DT, Freitag SK, Kieff D, et al. Radiographic patterns of orbital involvement in IgG4-related disease. Oprs. 2013;29(4):261–266.
- Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-relat4ed disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30. doi:10.3109/s10165-011-0571-z.
- McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part II: Clinical aspects. Oprs. 2015;31(3):167–178.
- Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with Rituximab in patients with active moderate to severe Graves’ Orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422–431. doi:10.1210/jc.2014-3014.
- Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized control trial of Rituximab in patients with Graves’ Orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432–441. doi:10.1210/jc.2014-2572.
- Li Y, Nishihara E, Hirokawa M, et al. Distinct clinical, serological, and sonographic characteristics of Hashimoto’s Thyroiditis based with and without IgG4-postitive plasma cells. J Clin Endocrinol Metab. 2010;95:1309–1317. doi:10.1210/jc.2009-1794.
- Wong AJ, Planck SR, Choi D, et al. IgG4 immunostaining and its implications in orbital inflammatory disease. PLoS ONE. 2014;9:e109847. doi:10.1371/journal.pone.0109847.